TL;DR The New York Blood Center Enterprises and the Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe’s inventory of over 30,000 units, including rare HLA-homozygous donors, and Biohub’s expertise in reprogramming immune cells. The resulting cell lines will be shared research resources for regenerative medicine, disease modelling, and cell therapy, addressing the field’s core bottleneck: the gap between laboratory biology and scalable, immune-compatible treatments Most of the umbilical cord blood collected at birth is discarded. The tissue is clamped, cut, and disposed of as medical waste, along with the stem cells it contains, cells that are immunologically naive, genetically diverse, and capable of being reprogrammed into virtually any cell type in the human body.…